-
公开(公告)号：US20220307040A1
公开(公告)日：2022-09-29
申请号：US17713533
申请日：2022-04-05
Applicant: CureVac AG
Inventor： Andreas THESS , Thomas SCHLAKE , Stefanie GRUND
IPC: C12N15/67 , A61K39/12 , C12N15/85 , A61K39/145 , A61K39/205 , C12N15/68
Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.
-
公开(公告)号：US20220136001A1
公开(公告)日：2022-05-05
申请号：US17576583
申请日：2022-01-14
Applicant: CureVac AG
Inventor： Andreas THESS
Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3′-UTR element.
-
公开(公告)号：US20220090092A1
公开(公告)日：2022-03-24
申请号：US17542430
申请日：2021-12-05
Applicant: CureVac AG
Inventor： Andreas THESS , Thomas SCHLAKE , Stefanie GRUND
IPC: C12N15/67 , C12N15/85 , A61K39/205 , C12N15/68 , A61K39/145 , A61K39/12
Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.
-
公开(公告)号：US20210128716A1
公开(公告)日：2021-05-06
申请号：US17139778
申请日：2020-12-31
Applicant: CureVac AG
Inventor： Andreas THESS , Thomas SCHLAKE , Jochen PROBST
Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US20210060181A1
公开(公告)日：2021-03-04
申请号：US17020517
申请日：2020-09-14
Applicant: CureVac AG
Inventor： Andreas THESS , Thomas SCHLAKE , Jochen PROBST
Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein. The present invention further describes a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
Patent Agency Ranking
公开(公告)号：US20200345831A1
公开(公告)日：2020-11-05
申请号：US16938136
申请日：2020-07-24
Applicant: CureVac AG
Inventor： Andreas THESS , Thomas SCHLAKE , Jochen PROBST
Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US20180312545A1
公开(公告)日：2018-11-01
申请号：US15774423
申请日：2016-11-09
Applicant: CureVac AG
Inventor： Patrick BAUMHOF , Susanne RAUCH , Aleksandra KOWALCZYK , Johannes LUTZ , Edith JASNY , Benjamin PETSCH , Andreas THESS , Thomas SCHLAKE , Mariola FOTIN-MLECZEK , Regina HEIDENREICH , Sandra LAZZARO , Fatma DÖNER , Wolfgang GROSSE
IPC: C07K14/005 , C07K14/205 , A61K39/145
CPC classification number: C12N15/00 , A61K39/12 , A61K2039/53 , C07K14/005 , C07K2319/00 , C12N2760/16122 , C12N2760/16134
Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.
-
公开(公告)号：US20180237817A1
公开(公告)日：2018-08-23
申请号：US15580121
申请日：2016-05-30
Applicant: CureVac AG
Inventor： Tilmann ROOS , Benyamin YAZDAN PANAH , Markus CONZELMANN , Andreas THESS , Dominik BUOB , Martin KUNZE , Veronika WAGNER
CPC classification number: C12P19/34 , C12N9/1007 , C12N9/1241 , C12N9/16 , C12N11/02 , C12N11/08 , C12Y201/01056 , C12Y201/01057 , C12Y207/0705 , C12Y301/03033
Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2′-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2′-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5′-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5′-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2′-O-methyltransferase.
-
公开(公告)号：US20180177894A1
公开(公告)日：2018-06-28
申请号：US15899336
申请日：2018-02-19
Applicant: CureVac AG
Inventor： Andreas THESS , Thomas SCHLAKE , Jochen PROBST
CPC classification number: A61K48/0066 , A61K39/00 , A61K48/00 , C07K14/505 , C07K16/32 , C07K2317/14 , C07K2317/24 , C12N15/63 , C12N15/67 , C12N15/85 , C12N2830/50 , C12N2840/105
Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein. The present invention further describes a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US20170247699A1
公开(公告)日：2017-08-31
申请号：US15590370
申请日：2017-05-09
Applicant: CureVac AG
Inventor： Andreas THESS
IPC: C12N15/113 , A61K48/00 , A61K39/00 , C12N15/85
Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.035 seconds)
